51 results about "Temozolomid" patented technology

The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

The invention discloses a drug-tolerant glioblastoma cell line of primary temozolomide and bevacizumab, a construction method and application of the cell line. The construction method comprises the following steps: obtaining tissue specimens of patients with drug-resistant glioblastoma cell of primary temozolomide and bevacizumab through clinical screening, primarily culturing tumor cells through an enzyme digestion method, and continuously extending generation to 50 generations to obtain a strain of drug-tolerant glioblastoma cell line of primary temozolomide and bevacizumab; the microbial preservation number of the drug-tolerant glioblastoma cell line of primary temozolomide and bevacizumab is CGMCC No.8205. The glioblastoma cell line, disclosed by the invention, is stable in characteristics, stably heritable and high in tolerance to temozolomide and bevacizumab; the cell generation cycle lasts about 48 hours; the glioblastoma cell line has strong invasiveness and tumorigenicity. The glioblastoma cell line constructed by the construction method has important application prospect in aspects of screening medicines for treating glioblastoma and researching nosogenesis of the glioblastoma, and the like.

The invention provides methods and compositions for treatment of a subject with a glioma that has failed treatment with temozolomide (TMZ) comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. The invention also provides a method of treating a cancer that exhibits increased Complex II activity in a subject comprising administration of a composition comprising a Coenzyme Q10 compound to the subject.

This invention relates to methods and drug products for treating proliferative disorders using intravenous formulations comprising temozolomide over a specific infusion time. These methods and drug products are particularly well-suited for patients who cannot swallow oral formulations. These methods and drug products also afford an added convenience to patients who are already receiving other therapeutic treatments.

Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.

Temozolomide nano-prodrug micelles comprise a hydrophilic shell and a hydrophobic core, the hydrophilic shell is polyoxazoline or polyethylene glycol, and the hydrophobic core is polytemozolomide. Its preparation method is: react polyoxazoline or polyethylene glycol with 4-cyano-4-pentanoic acid through esterification, and use the obtained product as a macromolecular RAFT reagent under the catalysis of azobisisobutyronitrile to react with Temozolomide-methyl methacrylate reacts to obtain an amphiphilic block polymer. The amphiphilic block polymer of the present invention can prolong the half-life of temozolomide. The two kinds of amphiphilic block polymer nanomicelles belong to the drug prodrug of temozolomide. At the same time, the micelle core can carry other anticancer drugs to achieve different Combination therapy of drugs. After the polyoxazoline-polytemozolomide micelles enter the tumor cells, they are cleaved in the acidic environment of the cancer cells, and the encapsulated drugs are quickly released, thereby producing a highly effective therapeutic effect, which solves the problem of slow release of the drug carrier drug and easy to produce anti-inflammatory effects. Medicinal issues.

The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs such as pemetrexed or irinotecan for treatment of cancer or drugs including atropine for treatment of organophosphate poisoning.

The invention provides application of a brain glioma temozolomide drug resistance detection marker molecule SCD1, and particularly relates to a reagent for detecting the expression quantity of SCD1 inbrain glioma cells and preparing a preparation for predicting drug resistance of brain glioma to temozolomide and application of an inhibitor of SCD1 in preparation of a preparation for promoting drug resistance sensitivity of the brain glioma to the temozolomide. It is first discovered that the expression quantity of SCD1 in the brain glioma cells is related to the drug resistance of the brain glioma to the temozolomide, and it discovers that the inhibitor of SCD1 can promote the drug resistance sensitivity of the brain glioma to the temozolomide. The application has important significance on research of treatment of the brain glioma.

The present invention relates to a composition for use in treating a glioma or ameliorating the effects of a glioma, particularly glioblastoma, wherein said composition comprises a first active agent selected from the group consisting of a compound of formula (I), or a pharmaceutically acceptable salt thereof, (I) and a second active agent, which is temozolomide, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Disclosed is a use of E2F6 as a target capable of increasing the sensitivity of temozolomide. Temozolomide is used for treating glioblastoma. E2F6 inhibitor and temozolomide treatment can increase the curability of glioblastoma. The invention provides scientific evidence for the pathogenesis and clinical treatment of glioblastoma from the clinical patient sample level, cell function level and molecular level.

The invention discloses an application of long-chain non-coding RNA TRALR. The present invention uses lncRNA sequencing to find that lncRNA TRALR is abnormally highly expressed in temozolomide-resistant glioma cell lines, and specifically interfering with the expression of lncRNA TRALR can significantly inhibit BMI1, up-regulate p21 levels, and promote cell cycle arrest and aging , increase the sensitivity of glioma temozolomide. Therefore, the reagents for detecting the expression of lncRNA TRALR can be used to prepare preparations for the diagnosis, prognosis, or sensitivity detection of glioma patients, providing a powerful tool for the diagnosis, prognosis, and chemotherapy sensitivity prediction of glioma patients. Based on molecular biology, it has far-reaching clinical significance and important promotion and application prospects.